Patents by Inventor Terence Seward Baker

Terence Seward Baker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Obtaining an improved therapeutic ligand
    Patent number: 11942188
    Abstract: Methods and associated apparatus involving designing a ligand ab initio that will bind to a binding site of a macromolecular target, or of identifying a modification to a ligand for improving the affinity of the ligand to a binding site of a macromolecular target, comprising using information about non-bonding, intra-molecular or inter-molecular atom to atom contacts extracted from a database of biological macromolecules to identify favoured regions adjacent to the binding site for particular atom types and modifying a candidate ligand to increase the intersection between atoms of the candidate ligand and the favoured regions. One or more steps of the methods may be performed by a computer.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: March 26, 2024
    Assignee: UCB Biopharma SRL
    Inventors: Jiye Shi, Terence Seward Baker, Alastair David Griffiths Lawson, Xiaofeng Liu
  • Expression vector encoding antibody molecule which binds IL-17A and IL-17F
    Patent number: 11919950
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: March 5, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Terence Seward Baker, Alastair David Griffiths Lawson
  • TAU-BINDING ANTIBODIES
    Publication number: 20230416350
    Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
    Type: Application
    Filed: June 30, 2023
    Publication date: December 28, 2023
    Inventors: DAVID EDWARD ORMONDE KNIGHT, TERENCE SEWARD BAKER, DAVID JAMES MCMILLAN, ROBERT ANTHONY GRIFFIN, GEORGES MAIRET-COELLO, PATRICK DOWNEY, JEAN-PHILIPPE COURADE
  • TAU-BINDING ANTIBODIES
    Publication number: 20230331833
    Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
    Type: Application
    Filed: June 30, 2023
    Publication date: October 19, 2023
    Inventors: KERRY LOUISE TYSON, TERENCE SEWARD BAKER, GEORGES MAIRET-COELLO, PATRICK DOWNEY, JEAN-PHILIPPE COURADE, DAVID EDWARD ORMONDE KNIGHT
  • Tau-binding antibodies
    Patent number: 11746145
    Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: September 5, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: Kerry Louise Tyson, Terence Seward Baker, Georges Mairet-Coello, Patrick Downey, Jean-Philippe Courade, David Edward Ormonde Knight
  • Tau-binding antibodies
    Patent number: 11732034
    Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: August 22, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: David Edward Ormonde Knight, Terence Seward Baker, David James McMillan, Robert Anthony Griffin, Georges Mairet-Coello, Patrick Downey, Jean-Philippe Courade
  • ANTI-ALPHA-SYNUCLEIN ANTIBODIES
    Publication number: 20220340648
    Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: February 28, 2022
    Publication date: October 27, 2022
    Inventors: Patrick DOWNEY, Kerry Louise TYSON, Marco KRIEK, Lorenzo DE LICHTERVELDE, Daniel John LIGHTWOOD, David James MCMILLAN, Peter Charles ELLIOT, Terence Seward BAKER
  • ANTI-ALPHA-SYNUCLEIN ANTIBODIES
    Publication number: 20220220192
    Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: January 26, 2022
    Publication date: July 14, 2022
    Inventors: Ralph ADAMS, Patrick DOWNEY, Terence Seward BAKER, Kerry Louise TYSON, Lorenzo DE LICHTERVELDE, Daniel John LIGHTWOOD, David James MCMILLAN
  • Anti-alpha synuclein antibodies
    Patent number: 11292831
    Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: April 5, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Patrick Downey, Kerry Louise Tyson, Marco Kriek, Lorenzo De Lichtervelde, Daniel John Lightwood, David James McMillan, Peter Charles Elliott, Terence Seward Baker
  • ANTIBODIES COMPRISING A POLYPEPTIDE INSERTED IN FRAMEWORK 3 REGION
    Publication number: 20220073581
    Abstract: The present invention provides antibodies comprising a variable (V) domain and an insert polypeptide, wherein the insert polypeptide is within the framework 3 region of the V domain.
    Type: Application
    Filed: July 10, 2019
    Publication date: March 10, 2022
    Inventors: Ralph Adams, Terence Seward Baker, Xiaofeng Liu
  • Anti-alpha-synuclein antibodies
    Patent number: 11261242
    Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 1, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Patrick Downey, Terence Seward Baker, Kerry Louise Tyson, Lorenzo De Lichtervelde, Daniel John Lightwood, David James McMillan
  • ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F
    Publication number: 20210309734
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: December 15, 2020
    Publication date: October 7, 2021
    Inventors: Ralph Adams, Terence Seward Baker, Alastair David Griffiths Lawson
  • TAU-BINDING ANTIBODIES
    Publication number: 20210139574
    Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
    Type: Application
    Filed: December 29, 2020
    Publication date: May 13, 2021
    Inventors: KERRY LOUISE TYSON, TERENCE SEWARD BAKER, GEORGES MAIRET-COELLO, PATRICK DOWNEY, JEAN-PHILIPPE COURADE, DAVID EDWARD ORMONDE KNIGHT
  • TAU-BINDING ANTIBODIES
    Publication number: 20210115121
    Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
    Type: Application
    Filed: December 29, 2020
    Publication date: April 22, 2021
    Inventors: DAVID EDWARD ORMONDE KNIGHT, TERENCE SEWARD BAKER, DAVID JAMES MCMILLAN, ROBERT ANTHONY GRIFFIN, GEORGES MAIRET-COELLO, PATRICK DOWNEY, JEAN-PHILIPPE COURADE
  • ANTI-ALPHA-SYNUCLEIN ANTIBODIES
    Publication number: 20210107971
    Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 15, 2021
    Inventors: Ralph ADAMS, Patrick DOWNEY, Terence Seward BAKER, Kerry Louise TYSON, Lorenzo DE LICHTERVELDE, Daniel John LIGHTWOOD, David James MCMILLAN
  • ANTI-ALPHA SYNUCLEIN ANTIBODIES
    Publication number: 20210101964
    Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 8, 2021
    Inventors: Patrick DOWNEY, Kerry Louise TYSON, Marco KRIEK, Lorenzo DE LICHTERVELDE, Daniel John LIGHTWOOD, David James MCMILLAN, Peter Charles ELLIOTT, Terence Seward BAKER
  • Tau-binding antibodies
    Patent number: 10906966
    Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: February 2, 2021
    Assignee: UCB BIOPHARMA SRL
    Inventors: Kerry Louise Tyson, Terence Seward Baker, Georges Mairet-Coello, Patrick Downey, Jean-Philippe Courade, David Edward Ormonde Knight
  • Tau-binding antibodies
    Patent number: 10889640
    Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: January 12, 2021
    Assignee: UCB BIOPHARMA SPRL
    Inventors: David Edward Ormonde Knight, Terence Seward Baker, David James McMillan, Robert Anthony Griffin, Georges Mairet-Coello, Patrick Downey, Jean-Philippe Courade
  • Obtaining an Improved Therapeutic Ligand
    Publication number: 20210005277
    Abstract: Methods and associated apparatus involving designing a ligand ab initio that will bind to a binding site of a macromolecular target, or of identifying a modification to a ligand for improving the affinity of the ligand to a binding site of a macromolecular target, comprising using information about non-bonding, intra-molecular or inter-molecular atom to atom contacts extracted from a database of biological macromolecules to identify favoured regions adjacent to the binding site for particular atom types and modifying a candidate ligand to increase the intersection between atoms of the candidate ligand and the favoured regions. One or more steps of the methods may be performed by a computer.
    Type: Application
    Filed: March 18, 2020
    Publication date: January 7, 2021
    Inventors: Jiye Shi, Terence Seward Baker, Alastair David Griffiths Lawson, Xiaofeng Liu
  • Endosomolytic agents for gene therapy
    Patent number: 10842884
    Abstract: Compounds of formula (I), wherein Ar is an aryl group optionally further substituted with one or more groups R3; A is a lipophilic, hydrophobic moiety; R1 is a phosphodiester, phosphotriester, thioether or amide group; X is an unsubstituted or substituted C6 to C24 alkylene or alkenylene group, which is optionally interrupted by one or more —NR9—, —O— or —S— linkages, R2 is —YC(R4)(R5)CO2R6; and pharmaceutically acceptable salts or solvates thereof are useful as endosomolytic agents particularly for the delivery of nucleic acids useful in gene therapy.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: November 24, 2020
    Assignee: UCB Biopharma SRL
    Inventors: Terence Seward Baker, Michael Anthony William Eaton, Timothy John Norman, James Petrie Turner